Welcome to our dedicated page for WORK Medical Technology Group news (Ticker: WOK), a resource for investors and traders seeking the latest updates and insights on WORK Medical Technology Group stock.
WORK Medical Technology Group LTD (Nasdaq: WOK) is a medical devices company that develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices through subsidiaries in China. Its news flow, as reflected in company press releases and SEC reports, spans product development, regulatory milestones, capital markets activity, and strategic collaborations.
Readers following WOK news can track updates on WORK Medical’s portfolio of medical consumables, including customized and multifunctional masks and other disposable devices, as well as its expansion into AI-enabled diagnostic equipment. A key recent theme is the company’s AI-Automated Human Blood Cell Morphology Analyzer, a Class II medical device developed by subsidiary Hunan Saitumofei. News items cover manufacturing approval from a Chinese regulatory authority, technical capabilities of the analyzer, and an exclusive distribution agreement with Shanghai Benke Medical Technology Co., Ltd. for East China.
WORK Medical’s news also includes announcements on equity investments and partnerships. The company has reported a 10% equity investment in Neologics Bioscience Inc., a Delaware-based medical technology firm focused on integrating artificial intelligence and medicine, and subsequent service agreements between Neologics and GemPharmatech Corporation. In addition, WORK Medical has disclosed a strategic cooperation agreement with Hong Kong Web3.0 Standardization Association Limited to explore blockchain and Real-world Asset technology applications.
Capital markets and listing-related developments form another important category of WOK news. The company has issued press releases on registered direct offerings, at-the-market offering arrangements, reverse stock splits, and communications from Nasdaq regarding minimum bid price compliance and potential delisting determinations. For investors and observers, the WOK news page on Stock Titan provides a centralized view of these disclosures, helping users review product, regulatory, financing, and governance announcements in one place.
WORK Medical (Nasdaq: WOK) will implement a 1-for-100 reverse stock split of its Class A and Class B ordinary shares, effective June 18, 2026.
Issued Class A shares will be reduced from 241,653,844 to about 2.42 million, with fractional shares rounded up, and the stock will keep trading on Nasdaq under WOK with new CUSIP G9767H133.
WORK Medical Technology Group (Nasdaq: WOK) participated as a partner and exhibitor at the 2026 CBA-China Annual Conference in Wuxi, China, held May 8–10, 2026.
The company highlighted its medical device business and strategic focus on AI+Digital Healthcare, aiming to build global partnerships and support its international growth strategy.
WORK Medical Technology Group (Nasdaq: WOK) has established a wholly owned U.S. subsidiary, Work Bio Technologies, incorporated in Nevada. The new entity will be the primary U.S. operational platform, focusing on supply chain management, product distribution, and direct business relationships to support WORK Medical’s global expansion and long-term growth strategy.
The subsidiary aims to integrate distribution, supply chain, regulatory compliance, and customer engagement across key global markets. CEO and Chairman Wu Shuang also serves as President, Secretary, Treasurer, and Director of Work Bio Technologies.
WORK Medical (Nasdaq: WOK) signed a strategic cooperation agreement with Novabioplus to combine AI algorithms with extensive protein data and reagent platforms.
The partners plan four “AI+” projects in protein, antibody, enzyme and peptide design, and to develop an AI-driven “BioToken” model that turns biological data and biopharmaceutical R&D outputs into verifiable digital assets within a healthcare-focused digital ecosystem.
WORK Medical (Nasdaq: WOK) announced it was named a Vice President Unit of Hong Kong Web3.0 Standardization Association and co‑authored an Asset Tokenization Whitepaper released April 22, 2026. The company described plans to advance medical real‑world asset tokenization, A2A payments, and stablecoin cross‑border settlement.
The release frames these steps as part of a strategic shift toward a tokenized, AI‑enabled healthcare infrastructure and notes prior alignment with Hong Kong's stablecoin framework effective August 1, 2025.
WORK Medical (Nasdaq: WOK) subsidiary Hunan Saitumofei granted Shanghai Benke exclusive distribution rights for the AI-Automated Blood Cell Morphology Analyzer (CM-B600) in East China (Jiangsu, Shanghai, Zhejiang) from Jan 1 to Dec 31, 2026.
The Agreement sets a minimum annual sales target of RMB 10 million and includes a RMB 1 million prepaid performance bond. The Analyzer received Class II manufacturing approval in Nov 2025, supports up to 150 samples per batch, average detection time ≤ 3 minutes per smear, classification accuracy ≥ 90% for major WBC types, identification of 17 WBC subtypes, and a database > 350,000 images.
WORK Medical Technology Group (Nasdaq: WOK) announced that its subsidiary Hunan Saitumofei received manufacturing approval from the Hunan Provincial Medical Products Administration for a Class II AI‑Automated Human Blood Cell Morphology Analyzer on December 29, 2025. The analyzer combines a main optical imaging unit and embedded analysis software to perform white blood cell differentials and quantify red blood cell and platelet morphology using deep‑learning algorithms.
Manufacturing is scheduled to begin in the first half of 2026. The company says the device aims to increase efficiency, consistency, and accuracy in microscopic exams, reduce manual workload and costs, and support early screening and quality control in hematology and oncology settings.
WORK Medical (Nasdaq: WOK) announced a 1-for-100 reverse stock split of its Class A and Class B ordinary shares, effective when markets open on December 29, 2025. The action was approved by the board and shareholders and is being effectuated primarily to maintain compliance with Nasdaq Marketplace Rule 5550(a)(2) on minimum bid price. Shares will continue to trade on the Nasdaq Capital Market under the symbol WOK with a new CUSIP G9767H125. Fractional shares will be rounded up to the next whole share; no fractional shares will be issued. The reverse split combines every 100 issued and outstanding Class A or Class B shares into one share, and does not change percentage ownership except for rounding adjustments.
WORK Medical (Nasdaq: WOK) announced that its subsidiary Neologics Bioscience entered a service agreement with GemPharmatech on Nov 4, 2025 to provide antibody R&D testing and in vitro validation services.
Under the Agreement, GemPharmatech will pay US$114,000 in total for services performed under work orders. WORK Medical previously invested $1.0 million in Neologics on Oct 21, 2025 and, as of Oct 29, 2025, holds a 10% equity interest following Delaware shareholder registration. Neologics operates an R&D lab in San Diego and focuses on AI-integrated preclinical drug screening and target discovery.
WORK Medical (NASDAQ: WOK) agreed to invest US$1 million in Neologics Bioscience to acquire a 10% equity interest via newly issued shares, on a post-investment basis. The transaction raises Neologics's total capital reserve to US$10 million and leaves the existing shareholder with a 90% stake.
WORK Medical gains governance rights tied to its 10% holding, a right of first refusal on future equity offers, and expects Neologics to complete registration and issue an equity certificate within 20 working days. Proceeds will support operations, R&D, market expansion, and hiring.